U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07453342) titled 'Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge' on March 01.
Brief Summary: This observational study aims to comprehensively characterize immune-related adverse events (irAEs) occurring during immune checkpoint inhibitor (ICI) therapy in cancer patients and to evaluate the safety and clinical outcomes of ICI rechallenge following irAE resolution.
In addition to detailed clinical data collection, the study incorporates biospecimen acquisition, when clinically indicated and feasible, including peripheral blood and organ-specific specimens (e.g., bronchoalveolar lavage fluid for ICI-relate...